All In Biotech

Drug Trial Radar · NCT00203034

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Last checked: Nov 20, 2026Latest source record: Mar 9, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 472 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

472

Actual

Start

May 2000

Primary completion

Jan 2003

Study completion Jan 2003

Sponsor

Sponsor type
Industry
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo

Conditions

  • Parkinson's Disease

Interventions

  • rasagiline mesylateDrug

    0.5 mg rasagiline mesylate oral once daily

  • 1.0 mg rasagiline mesylateDrug

    1.0 mg rasagiline mesylate oral once daily

  • PlaceboOther

    oral placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the mean total daily "OFF" timeTime frame: 26 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Rush - Presbyterian St. Luke's Medical Center

    Chicago, Illinois

  • Columbia - Presbyterian Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Baylor College of Medicine

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.